HUTCHMED (China) vs Nuvation Bio
HCM and NUVB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HCM and NUVB compare
Nuvation Bio grew revenue faster over the last twelve months (654% versus −13.0% for HUTCHMED (China)).
HUTCHMED (China) keeps more of each dollar of sales as profit, with a net margin of 83.3% compared with −67.4% at Nuvation Bio.
HUTCHMED (China) scores higher on the StockData Score (5 against 4 for Nuvation Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HCM | NUVB |
|---|---|---|
| Size and price | ||
| Market cap | – | $1.4B |
| Share price | $14.90 | $3.99 |
| Change, 1 year | −2.5% | −19.1% |
| Change, 5 years | −51.5% | −55.9% |
| Beta (5Y) | 0.97 | 1.45 |
| Employees | 109 | 298 |
| StockData Score | ||
| Total score | 5 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 3 (better) | 1 |
| Health score | 2 | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 6.9× |
| P/B | – | 6.1× |
| Fair value | – | $1.94 |
| Margin of safety | – | −105% |
| Growth | ||
| Revenue growth (TTM) | −13.0% | 654% (better) |
| Revenue growth, 5Y average | 19.2% | – |
| Net income growth (TTM) | 1111% | – |
| EPS growth (TTM) | 1200% | – |
| Profitability | ||
| Gross margin | 38.7% | – |
| Operating margin | −7.1% (better) | −61.2% |
| Net margin | 83.3% (better) | −67.4% |
| FCF margin | −14.4% | – |
| Return on equity | 36.7% (better) | −49.1% |
| Financial health | ||
| Debt / equity | 0.09 | 0.03 (better) |
| Interest coverage | −13.7× | −5.9× (better) |
| Current ratio | 5.64 | 7.45 (better) |
| Altman Z-score | – | 0.06 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.51% | 66.5% |
| Held by insiders | 0.44% | 24.6% |
| Insider net buying, 12 months | – | −$4.5M |
| Superinvestors holding | – | 2 |
| Short interest, % of float | – | 23.4% |
Go deeper
- HCM stock overview
- HCM income statement
- HCM valuation and score
- NUVB stock overview
- NUVB income statement
- NUVB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.